Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient.
L Mole, D Israelski, J Bubp...
https://pubmed.ncbi.nlm.nih.gov/8417175/Completed
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2008-08-04
8
Participants Needed
1
Research Sites
N/A
Total Duration
To determine if a pharmacokinetic (blood level) interaction exists between zidovudine (AZT) and oxazepam in the HIV-infected patient. Benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs and are commonly used therapeutically for patients with chronic disease. This study is important because of the potential for toxicity resulting from a reaction between AZT and benzodiazepines and the likelihood of frequent use of the combination of these drugs in patients with HIV infection.
CONDITIONS
The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
Inclusion Criteria
Concurrent Medication:
Required:
Allowed:
Patients must be:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Concurrent Medication:
Excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 30 days of study entry:
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
L Mole, D Israelski, J Bubp...
https://pubmed.ncbi.nlm.nih.gov/8417175/National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor